是没有的产品在您的购物车
Pingclinicinc's Story Links
By Daniel Costello, Los Angeles Times Staff Writer
December 6, 2007
Genentech shares plunge. The vote could be a sign of tougher standards at the agency.
A Food and Drug Administration panel dealt a sharp blow to biotech giant Genentech Inc. on Wednesday by refusing to recommend approval for the company's high-profile drug Avastin as a treatment for breast cancer.
The news signaled to industry experts that federal regulators appear to be adopting stricter standards for drug approvals. It also sent the company's shares into free fall -- down more than 8% before trading was stopped in the afternoon.









“这是世界最好的有关结合现代医学和古老的东方医学智慧养生之道。 ”
Recent Comments
2 天 18 小时 前
3 周 1 天 前
7 周 1 天 前
16 周 2 小时 前
16 周 1 天 前
19 周 2 天 前
23 周 1 天 前
24 周 4 小时 前
27 周 5 天 前
28 周 6 天 前